ANSWER: C

Rationale:

Thyroxine-binding globulin (TBG) is the principal plasma transport protein for thyroid hormones, binding approximately 70% of circulating T4. TBG is a glycoprotein synthesized in the liver and cleared renally. In nephrotic syndrome — characterized by heavy proteinuria — TBG is lost in the urine along with other plasma proteins of similar molecular weight (albumin, transferrin). This reduces total TBG concentration and therefore the total T4-carrying capacity of plasma. However, because only the unbound (free) fraction of T4 is biologically active and available for pituitary feedback, the HPT axis responds by transiently increasing TSH until sufficient additional T4 is secreted to restore the free fraction to its set point. The new equilibrium has lower total T4 and lower TBG, but normal free T4 and normal TSH — indistinguishable from euthyroidism on functional assessment. The same pattern is seen with other causes of TBG reduction: androgens (which decrease hepatic TBG synthesis), glucocorticoids (which decrease TBG synthesis and increase TBG clearance), and severe liver disease (reduced synthesis). Free T4 measurement — not total T4 — is the correct test for assessing thyroid status in patients with altered TBG.

• Option A: Option A is incorrect because complement-mediated oxidative destruction of T4 molecules does not occur in nephrotic syndrome; the mechanism is protein loss through the damaged glomerular filtration barrier, not chemical destruction of the hormone.
• Option B: Option B is incorrect because TBG reduction in nephrotic syndrome is primarily due to urinary loss, not impaired hepatic synthesis; hepatic synthesis of TBG is not significantly reduced by the amino acid depletion of nephrotic syndrome, which affects albumin most profoundly.
• Option D: Option D is incorrect because renal 5'-deiodination contributes to peripheral T3 generation but this pathway is not selectively impaired in nephrotic syndrome in a way that reduces total T4; the predominant mechanism is TBG loss, not altered deiodination.
• Option E: Option E is incorrect because there is no erythropoietin-TSH axis and nephrotic syndrome does not impair pituitary TSH secretion; TSH is normal in this patient, confirming intact pituitary function.

ANSWER: A

Rationale:

After NIS concentrates iodide within the thyrocyte at the basolateral membrane, the iodide must be transported across the apical membrane into the follicular lumen to reach thyroid peroxidase (TPO), which is anchored on the luminal face of the apical membrane. This apical iodide efflux step is mediated primarily by pendrin, an anion exchanger encoded by SLC26A4 that exchanges intracellular iodide for extracellular chloride. Unlike NIS, which is a sodium-dependent secondary active transporter located on the basolateral membrane and uses the inward sodium gradient to drive iodide uptake against its concentration gradient, pendrin is a facilitated exchanger that does not use sodium and operates on the opposite — apical — pole of the thyrocyte. Loss-of-function mutations in SLC26A4 cause Pendred syndrome, an autosomal recessive disorder characterized by sensorineural hearing loss and goiter with impaired iodide organification — directly demonstrating the physiological importance of pendrin for thyroid hormone synthesis. Other anion channels including CFTR (cystic fibrosis transmembrane conductance regulator) may also contribute to apical iodide transport in some species.

• Option B: Option B is incorrect because NIS is not recycled to the apical membrane to function in reverse; NIS is constitutively expressed on the basolateral membrane and its trafficking is regulated by TSH, but apical transport requires a structurally distinct transporter (pendrin) rather than a repurposed NIS.
• Option C: Option C is incorrect because TPO is not a transporter and does not physically move iodide across the membrane; TPO is an enzyme that oxidizes iodide using hydrogen peroxide and then catalyzes its attachment to tyrosyl residues on thyroglobulin — transport and organification are sequential but mechanistically separate events.
• Option D: Option D is incorrect because ClC-5 is a chloride/proton antiporter predominantly expressed in endosomes and renal proximal tubules, not a thyroid apical iodide transporter; voltage-gated chloride channels are not the established mechanism for apical iodide efflux.
• Option E: Option E is incorrect because thyroglobulin does not create a transmembrane concentration gradient by binding free iodide in the lumen; iodide must first be transported across the apical membrane by a carrier protein, and thyroglobulin's role is to serve as the substrate for organification after iodide has already entered the lumen.

ANSWER: E

Rationale:

These are two mechanistically distinct pathways that both reduce T3 availability but do so in completely different tissue compartments and through different enzymes. The DIO2 Thr92Ala polymorphism (rs225014, substituting alanine for threonine at position 92) reduces the catalytic efficiency of type 2 deiodinase (D2) — the enzyme responsible for intracellular T4-to-T3 conversion in D2-expressing tissues including the brain, pituitary, brown adipose tissue, heart, and skeletal muscle. Because D2 generates T3 locally within cells for nuclear receptor activation, impaired D2 activity reduces intracellular T3 in neurons and other D2-dependent cells even when circulating T3 levels appear normal; the peripheral circulation is primarily supplied by D1, which is not affected by this variant. Propylthiouracil (PTU), by contrast, inhibits type 1 deiodinase (D1) — the enzyme expressed in the liver, kidney, thyroid, and skeletal muscle responsible for generating the majority of circulating T3 from T4 and for clearing reverse T3 (rT3). PTU also inhibits thyroid peroxidase (TPO), blocking new hormone synthesis. The key distinction is tissue compartment: Thr92Ala impairs intracellular D2-mediated T3 generation in D2-expressing tissues without reducing circulating T3, while PTU reduces circulating T3 by inhibiting D1 in peripheral organs.

• Option A: Option A is incorrect because the DIO2 gene encodes type 2 deiodinase (D2), not type 1 deiodinase (D1); the Thr92Ala variant selectively impairs D2 activity, and its effects are on intracellular T3 in D2-expressing tissues, not on circulating T3 production from D1.
• Option B: Option B is incorrect because the DIO2 Thr92Ala variant reduces deiodinase enzyme efficiency, not receptor structure; thyroid hormone receptors (TRs) are encoded by separate genes (THRA, THRB) that are not affected by DIO2 variants.
• Option C: Option C is incorrect because the Thr92Ala variant does not upregulate D3; D3 is encoded by DIO3, not DIO2, and increased D3 expression is associated with critical illness and fetal development, not with the DIO2 polymorphism.
• Option D: Option D is incorrect because the DIO2 Thr92Ala variant affects deiodinase catalytic activity in peripheral D2-expressing tissues, not TRbeta2 receptor affinity in the pituitary; patients with this variant do not typically have elevated TSH, which distinguishes impaired D2 efficiency from a pituitary receptor defect.

ANSWER: B

Rationale:

Thyroid hormone receptors (TRs) are unique among nuclear receptors in that they bind their DNA response elements constitutively — both in the presence and absence of ligand. In the unliganded state, TR-bound promoters are actively silenced rather than simply quiescent. The mechanism involves recruitment of nuclear receptor corepressor proteins NCoR1 (nuclear receptor corepressor 1) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor), which bind to the ligand-binding domain of unliganded TR through specific CoRNR box (corepressor nuclear receptor box) motifs. NCoR1 and SMRT serve as scaffolds that recruit class I and class II histone deacetylases (HDACs), including HDAC3 (which directly associates with NCoR1) and members of the HDAC4/5/7/9 family. HDACs remove acetyl groups from the epsilon-amino groups of lysine residues on histone H3 and H4 tails, reversing the relaxed (active) chromatin state and restoring a condensed, transcriptionally repressive chromatin structure. When T3 binds the ligand-binding domain of TR, it induces rotation of helix 12 (the activation function 2 helix), which displaces the CoRNR motif and recruits the LXXLL motifs of p160 coactivators (SRC-1/NCoA1, SRC-2/GRIP1, SRC-3/AIB1), which bring histone acetyltransferase (HAT) activity that reopens chromatin for transcription.

• Option A: Option A is incorrect because TRs reside constitutively in the nucleus — they are not cytoplasmic in the unliganded state and are not regulated by immunophilin chaperones of the FKBP family; that mechanism describes glucocorticoid receptors and other steroid hormone receptors.
• Option C: Option C is incorrect because the corepressor mechanism of unliganded TRs operates through HDAC-mediated histone deacetylation, not PRC2-mediated H3K27 trimethylation; PRC2 establishes a different, more permanent epigenetic silencing mark associated with developmental gene regulation, not the rapid and reversible T3-responsive transcriptional switch.
• Option D: Option D is incorrect because TR-mediated repression is not due to steric occlusion of the TATA box; TRs bind to TRE sequences distinct from the core promoter and act through chromatin remodeling, not physical blockade of RNA polymerase assembly sites.
• Option E: Option E is incorrect because the unliganded TR repression mechanism does not operate through MED12/CDK8 sequestration; the mediator complex has roles in transcriptional activation downstream of TR, but the primary repression mechanism is the NCoR1/SMRT-HDAC axis as described.

ANSWER: D

Rationale:

The Wolff-Chaikoff effect requires sustained high intracellular iodide concentrations to maintain organification inhibition. The thyroid escapes this effect through autoregulatory downregulation of NIS expression — specifically, high intracellular iodide concentrations suppress NIS gene transcription and accelerate NIS protein turnover at the basolateral membrane, reducing the rate of iodide transport into the thyrocyte. As intracellular iodide accumulation diminishes below the inhibitory threshold, the organification block lifts and thyroid hormone synthesis resumes despite continued high extracellular iodide. This escape mechanism explains the fundamental limitation of iodide as an antithyroid agent: it works acutely (typically within hours of loading) but the gland adapts within days to weeks, making iodide suitable only for short-term indications such as preoperative preparation and thyroid storm adjunct therapy. In patients who cannot escape the Wolff-Chaikoff effect — particularly those with pre-existing thyroid disease, those taking lithium, or neonates — prolonged iodide exposure can cause hypothyroidism.

• Option A: Option A is incorrect because the escape mechanism does not involve TPO upregulation; TPO expression is not dramatically altered during Wolff-Chaikoff escape, and increased TPO protein alone would not resolve the underlying inhibition, which is caused by high intracellular iodide species rather than insufficient enzyme.
• Option B: Option B is incorrect because TSH receptor upregulation is not the mechanism of Wolff-Chaikoff escape; TSH receptor expression is regulated by TSH levels and long-term thyroid status, not by acute iodide loading, and the pituitary-thyroid axis operates on a timescale of days to weeks — too slow to explain the rapid escape.
• Option C: Option C is incorrect because lysosomal proteases are involved in thyroglobulin endocytosis and T4/T3 release — not in the resolution of organification inhibition; there are no identified iodide-binding inhibitory proteins that are degraded during Wolff-Chaikoff escape.
• Option E: Option E is incorrect because pendrin exports iodide to the follicular lumen for organification under normal conditions, but the Wolff-Chaikoff effect impairs the TPO-mediated organification step itself; increasing apical iodide export via pendrin would not restore organification if TPO remains inhibited, and enhanced pendrin activity is not the established escape mechanism.

ANSWER: C

Rationale:

Distinguishing type 1 from type 2 amiodarone-induced thyrotoxicosis is clinically critical because they require diametrically opposite treatments — thionamides plus perchlorate for type 1 (which involves active iodine-driven new hormone synthesis) versus glucocorticoids for type 2 (which involves destructive thyroiditis with release of preformed hormone). Color Doppler ultrasonography is the most practical first-line imaging tool for this distinction. Type 1 AIT occurs in patients with pre-existing nodular or diffuse thyroid disease in whom iodide loading drives autonomous synthesis; the resulting active follicular metabolism produces marked vascularity on color Doppler, similar to the hypervascular pattern seen in Graves' disease. Type 2 AIT occurs in a structurally normal thyroid gland where direct amiodarone toxicity causes follicular cell necrosis and destructive thyroiditis; this destructive process reduces or eliminates follicular vascularity, producing an avascular or markedly hypovascular pattern on color Doppler. Mixed-type AIT (features of both) shows intermediate vascularity and may require combined therapy. Thyroid scintigraphy is also used but is often unreliable in iodine-loaded patients because the amiodarone iodide burden suppresses radiotracer uptake in both types.

• Option A: Option A is incorrect because type 1 AIT does not produce a cystic gland pattern and type 2 does not produce hyperechoic calcifications; grayscale morphology is less discriminating than Doppler vascularity for distinguishing AIT types, and calcifications are associated with long-standing thyroid disease or malignancy, not acute thyroiditis.
• Option B: Option B is incorrect because radioiodine uptake is suppressed in both type 1 and type 2 AIT due to competitive iodide loading from amiodarone; NIS is not released into the circulation by destructive thyroiditis, and scintigraphy cannot reliably differentiate the two types in amiodarone-loaded patients.
• Option D: Option D is incorrect because homogeneous enlargement from diffuse follicular hyperplasia is characteristic of Graves' disease or iodine deficiency goiter; type 1 AIT typically shows pre-existing nodular or heterogeneous thyroid architecture, not homogeneous enlargement from de novo hyperplasia.
• Option E: Option E is incorrect because the described central-vs-peripheral uptake pattern on scintigraphy does not correspond to a recognized feature of AIT types; TSH-driven synthesis in AIT is not restricted to the isthmus, and this pattern is not part of the established diagnostic framework for differentiating type 1 from type 2.

ANSWER: A

Rationale:

Levothyroxine replacement dosing is weight-based, with full replacement requiring approximately 1.6 mcg/kg/day in healthy adults with complete hypothyroidism (such as post-thyroidectomy or post-radioiodine ablation). For this 68 kg patient, the calculated full replacement dose is approximately 109 mcg/day, which would typically be rounded to the nearest available tablet size (100 or 112 mcg). This weight-based approach reflects the direct relationship between body mass and total thyroid hormone requirement. However, important patient subgroups require a cautious, low-dose initiation strategy: elderly patients (in whom the cardiovascular system may not tolerate the abrupt restoration of normal metabolic rate), patients with known or suspected ischemic heart disease or arrhythmias (in whom sudden normalization of thyroid status can precipitate angina, myocardial infarction, or atrial fibrillation), and patients who have retained residual thyroid function (in whom full replacement dosing would cause iatrogenic thyrotoxicosis). These patients are started at 12.5–25 mcg/day and titrated upward by 12.5–25 mcg every 4–6 weeks with clinical and biochemical monitoring.

• Option B: Option B is incorrect because 2.4 mcg/kg/day substantially overestimates the full replacement dose; this dose would produce iatrogenic thyrotoxicosis in most patients and the higher figure does not account for the actual bioavailability of levothyroxine tablets, which averages 70–80% under ideal conditions.
• Option C: Option C is incorrect because fixed-dose initiation without weight adjustment is not the standard approach; starting all adults at 100 mcg/day would significantly underdose heavier patients and potentially overdose lighter patients, and weight-based calculation is performed at initiation rather than deferred to the first TSH check.
• Option D: Option D is incorrect because the 1.6 mcg/kg/day principle applies to all adults with overt hypothyroidism regardless of etiology — not only post-ablation patients; patients with autoimmune hypothyroidism who have significant residual function may require less, but the calculation provides the target ceiling dose rather than the initiation dose.
• Option E: Option E is incorrect because 0.8 mcg/kg/day substantially underestimates the required dose and would leave most patients biochemically hypothyroid; peripheral deiodination does not double effective drug potency — it is already factored into the established 1.6 mcg/kg/day dosing parameter derived from clinical outcome studies.

ANSWER: E

Rationale:

Deiodinase nomenclature is based on the ring position from which iodine is removed. Thyroxine (T4) has an inner ring (the tyrosine-derived phenolic ring bearing the 3,5 iodines) and an outer ring (the phenol ring bearing the 3',5' iodines). Outer-ring (5'-) deiodination removes an iodine from the outer ring and generates the biologically active T3 from T4 — this is the activating pathway performed by D1 and D2. Inner-ring (5-) deiodination removes an iodine from the inner ring and generates inactive reverse T3 (rT3) from T4 — this is the inactivating pathway performed by D3. Additionally, D3 performs inner-ring deiodination of T3 itself, removing an iodine from T3's inner ring to generate 3,3'-diiodothyronine (T2), which is biologically inactive. These two D3-catalyzed reactions — T4→rT3 and T3→T2 — together constitute the principal thyroid hormone inactivation pathway. D3 is expressed at very high levels in the placenta and fetal liver and brain during development, where it serves a critical protective function: by inactivating both T4 and T3 before they can reach fetal tissues in biologically active concentrations, D3 prevents premature stimulation of fetal growth, neuronal differentiation, and metabolic programming by maternal thyroid hormones during critical developmental windows. D3 is also upregulated in peripheral tissues during critical illness (contributing to sick euthyroid syndrome) and in solid tumors (producing "consumptive hypothyroidism").

• Option A: Option A is incorrect because D3 does not perform outer-ring 5'-deiodination; D3 exclusively performs inner-ring 5-deiodination, generating inactive metabolites rather than active T3, which is the opposite of D1 and D2 activity.
• Option B: Option B is incorrect because D3 performs inner-ring deiodination (producing rT3, not T3); the products of inner-ring and outer-ring deiodination of T4 are structurally and biologically distinct — rT3 is inactive, while T3 is the active hormone.
• Option C: Option C is incorrect because the ring position labeling is not reversed; outer-ring 5'-deiodination by D1/D2 generates T3 (activating), and inner-ring 5-deiodination by D3 generates rT3 (inactivating) — the conventional designations are correct as stated.
• Option D: Option D is incorrect because D3 does act on T3 as well as T4; D3-catalyzed inner-ring deiodination of T3 to T2 is an established and physiologically important reaction, particularly in fetal tissues and the placenta where both T4 and T3 must be inactivated to protect the developing fetus.

ANSWER: B

Rationale:

Thyroglobulin (Tg) is a large homodimeric glycoprotein with a molecular weight of approximately 660 kDa, making it one of the largest secreted proteins in the body. It is synthesized in the rough endoplasmic reticulum of thyroid follicular cells, processed through the Golgi apparatus (where extensive glycosylation occurs), and secreted by exocytosis into the follicular lumen, where it accumulates as colloid — the viscous material visible in thyroid follicles on histological sections. Within the follicular lumen, Tg performs two simultaneous and essential functions: first, it serves as the molecular scaffold on which thyroid peroxidase (TPO) catalyzes organification (covalent attachment of iodide to tyrosyl residues at specific positions on the Tg polypeptide chain, forming MIT and DIT) and coupling (oxidative joining of iodotyrosyl residues to form T4 and T3 still covalently embedded in the Tg backbone); and second, it serves as the long-term storage matrix for thyroid hormones, with each Tg molecule containing approximately 2–3 T4 molecules and less than one T3 molecule under normal iodine sufficiency. When TSH stimulates hormone secretion, follicular cells endocytose colloid vesicles containing iodinated Tg; lysosomal proteases then cleave T4 and T3 from the Tg backbone, and the liberated hormones are secreted across the basolateral membrane into capillary blood. Serum Tg measurement is clinically useful as a tumor marker after total thyroidectomy for differentiated thyroid cancer — any detectable Tg indicates persistent or recurrent thyroid tissue.

• Option A: Option A is incorrect because thyroglobulin is a large dimeric protein (~660 kDa), not a 28 kDa monomer; 28 kDa corresponds roughly to TSH, not Tg, and Tg is not degraded immediately after organification — it serves as the durable colloid storage form of thyroid hormones for days to weeks.
• Option C: Option C is incorrect because thyroglobulin is a water-soluble glycoprotein, not a lipoprotein, and thyroid hormones are stored in the follicular lumen within the Tg backbone as colloid, not within thyrocyte membranes.
• Option D: Option D is incorrect because thyroglobulin is not a transmembrane protein; it is secreted into the follicular lumen as a soluble protein and must be retrieved by endocytosis of colloid before proteolytic liberation of T4 and T3 can occur.
• Option E: Option E is incorrect because thyroglobulin (Tg) and thyroxine-binding globulin (TBG) are entirely distinct proteins with different structures, tissue expression, and functions; TBG is a 54 kDa monomeric plasma transport protein encoded by SERPINA7, while Tg is a 660 kDa dimeric follicular colloid protein encoded by TG.

ANSWER: D

Rationale:

Immune checkpoint inhibitors — including anti-PD-1 agents (pembrolizumab, nivolumab), anti-PD-L1 agents (atezolizumab, durvalumab), and anti-CTLA-4 agents (ipilimumab) — disrupt the normal inhibitory checkpoints that prevent autoreactive T cells from attacking self-tissue. Among the most common immune-related adverse events are thyroid complications, occurring in 5–20% of patients depending on agent and combination. The characteristic pattern is painless thyroiditis driven by T-cell-mediated follicular destruction: inflammatory infiltration and direct cytotoxicity by autoreactive T cells (and to a lesser extent autoreactive B cells) cause follicular cell destruction that releases stored thyroid hormones into the circulation, producing a transient destructive thyrotoxic phase lasting approximately 2–6 weeks. As the preformed hormone is cleared and the follicular reserve is depleted by ongoing inflammation, the patient transitions through euthyroidism into hypothyroidism — which is frequently permanent because the ongoing immune process continues to damage follicular cells even after TSH-stimulated regeneration attempts. Long-term levothyroxine replacement is required in most patients who develop ICI-induced hypothyroidism. Thyroid function monitoring every 4–6 weeks during the first year of ICI therapy is recommended by major oncology guidelines.

• Option A: Option A is incorrect because ICI-induced thyroid disease most commonly follows a destructive thyroiditis pattern, not Graves-like TSH receptor antibody-mediated sustained hyperthyroidism; TRAb generation is an uncommon ICI thyroid complication, and the predominant pattern described — transient hyperthyroid followed by hypothyroidism — is thyroiditis, not Graves disease.
• Option B: Option B is incorrect because ICI thyroiditis is immune-mediated by autoreactive lymphocytes, not viral cytopathic effect; there is no viral mechanism, and the outcome is frequently permanent hypothyroidism rather than invariable return to euthyroidism.
• Option C: Option C is incorrect because ICIs do not cause iodine-excess thyrotoxicosis through intracellular iodine release from lymphocytes; this mechanism is not a recognized pathway of ICI thyroid toxicity, and the clinical pattern of ICI thyroiditis (destructive thyrotoxicosis followed by hypothyroidism) is entirely different from the iodine-excess pattern.
• Option E: Option E is incorrect because thyroid dysfunction occurs with single-agent ICI therapy as well as with combination regimens; anti-PD-1 and anti-PD-L1 monotherapy causes clinically significant thyroid adverse events in 5–10% of patients, and monitoring is universally recommended regardless of combination status.

ANSWER: C

Rationale:

Of the three plasma transport proteins for thyroid hormones, thyroxine-binding globulin (TBG) is the quantitatively dominant and clinically most important. TBG — a 54 kDa monomeric glycoprotein encoded by SERPINA7 and synthesized in the liver — binds approximately 70% of circulating T4 and 80% of circulating T3. It has the highest binding affinity for T4 among the three proteins (Kd approximately 10^-10 M), meaning it binds T4 tightly and releases it slowly. Transthyretin (TTR, formerly called thyroxine-binding prealbumin) — a 55 kDa tetrameric protein synthesized in the liver, choroid plexus, and retinal pigment epithelium — binds approximately 15% of T4 with intermediate affinity; it also transports retinol (vitamin A) via retinol-binding protein. Albumin, despite its high plasma concentration, has very low affinity for T4 and binds the remaining 10–15% of T4 loosely. The free fraction of T4 (approximately 0.02% of total T4) is the only biologically active and pituitary-feedback-relevant fraction. TBG is clinically the most important protein because changes in TBG concentration are the most common cause of total T4 abnormalities that do not reflect true thyroid dysfunction: TBG rises with estrogen, pregnancy, oral contraceptives, tamoxifen, and hepatitis (raising total T4); TBG falls with androgens, glucocorticoids, nephrotic syndrome, liver failure, and some drugs (lowering total T4) — in all cases free T4 and TSH remain normal in a euthyroid individual.

• Option A: Option A is incorrect because TBG binds approximately 70% of T4, not 15%; transthyretin binds approximately 15%, not 70%; the values are reversed.
• Option B: Option B is incorrect because TBG is the major T4-binding protein at approximately 70%, not 10%; transthyretin binds approximately 15%, not 70%; and the free fraction of T4 is approximately 0.02%, not 0.5%.
• Option D: Option D is incorrect because TBG and transthyretin do not bind equal proportions of T4; TBG (70%) is far more dominant than transthyretin (15%), and equal distribution does not reflect the actual binding fractions.
• Option E: Option E is incorrect because TBG binds T4 with high affinity and low capacity (not the reverse as stated), and albumin binds with low affinity and high capacity; T4 release to tissues depends primarily on the free fraction and the equilibrium with all binding proteins, not on albumin high-affinity release specifically.

ANSWER: A

Rationale:

The TSH receptor (TSHR) is a member of the leucine-rich repeat subfamily of G-protein-coupled receptors. At physiological TSH concentrations, the receptor couples primarily to the Gs alpha subunit, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP). The resulting activation of protein kinase A (PKA) drives the full program of thyroid follicular cell function: upregulation of NIS gene expression and NIS protein trafficking to the basolateral membrane (increasing iodide trapping), activation of TPO-mediated organification and coupling, stimulation of thyroglobulin synthesis and secretion into the follicular lumen, endocytosis of colloid, and lysosomal proteolysis of thyroglobulin to liberate T4 and T3 for secretion. The cAMP pathway also drives thyroid follicular cell differentiation and proliferation, though at supraphysiological concentrations the TSHR can additionally couple to Gq (activating PLC) — a secondary pathway that contributes to the mitogenic response and is clinically relevant in the pathogenesis of some TSH receptor-activating mutations. This signaling is directly analogous to the basis for recombinant human TSH (rhTSH, thyrogen) used clinically to stimulate I-131 uptake in thyroid cancer surveillance.

• Option B: Option B is incorrect because TSHR is a GPCR, not a receptor tyrosine kinase; the PI3K/Akt pathway may be activated downstream of Gs/cAMP signaling as a secondary effector in some cell types, but the primary TSH signaling cascade in thyroid follicular cells is Gs/adenylyl cyclase/cAMP/PKA.
• Option C: Option C is incorrect because TSHR couples primarily to Gs, not Gq, at physiological concentrations; Gq/PLC/IP3 signaling is the mechanism of TRH at the pituitary thyrotroph — not of TSH at the thyroid follicular cell.
• Option D: Option D is incorrect because TSHR couples to Gs (stimulatory), not Gi (inhibitory); Gi-coupled receptors reduce cAMP, which is the opposite of what TSH signaling produces, and MAPK activation is a secondary mitogenic pathway rather than the primary driver of thyroid hormone synthesis.
• Option E: Option E is incorrect because TSHR is a GPCR, not a ligand-gated ion channel; thyroglobulin tyrosyl residues do not require phosphorylation before organification — they are directly iodinated by TPO-mediated oxidative chemistry using hydrogen peroxide as the oxidant.

ANSWER: E

Rationale:

Standard levothyroxine tablet absorption involves two sequential pH-dependent steps: first, the tablet must disintegrate and dissolve in gastric acid to release levothyroxine in solution; second, the dissolved levothyroxine is absorbed predominantly in the jejunum and upper ileum. Under normal gastric acid conditions, this process is relatively efficient. However, when intragastric pH is elevated — from proton pump inhibitor therapy, H2-blocker use, autoimmune gastritis with achlorhydria, or H. pylori-associated gastric atrophy — tablet dissolution is impaired and levothyroxine bioavailability falls by 15–25% or more. Soft gelatin capsule formulations (brand name Tirosint in the US) contain levothyroxine dissolved in glycerin and gelatin, eliminating the tablet dissolution requirement; the soft capsule shell disperses rapidly in the stomach regardless of pH, releasing levothyroxine already in a bioavailable form. Liquid levothyroxine solution similarly bypasses the dissolution step entirely. Multiple pharmacokinetic studies have confirmed that these formulations achieve more consistent and higher bioavailability than standard tablets in patients with elevated intragastric pH. Patients who require PPIs, antacids, or those with achlorhydric states are the primary candidates for these alternative formulations.

• Option A: Option A is incorrect because soft gelatin capsules and liquid formulations do not contain chelating agents; the formulation advantage is the elimination of tablet dissolution, not chemical binding of competing ions — patients still need to separate calcium and iron supplements by several hours even with these formulations.
• Option B: Option B is incorrect because soft gelatin capsules and liquid formulations are not enteric-coated and do not selectively bypass the stomach; they disperse in the stomach like conventional capsules and release levothyroxine in a pre-dissolved state at whatever pH is present.
• Option C: Option C is incorrect because levothyroxine is absorbed by passive diffusion and facilitated transport across intestinal epithelium regardless of formulation; there is no lipophilic carrier system in approved levothyroxine formulations, and this mechanism is not the basis for their improved bioavailability.
• Option D: Option D is incorrect because soft gelatin capsules and liquid levothyroxine formulations contain the same absolute levothyroxine dose per unit as the equivalent tablet strength; the improved bioavailability reflects better absorption efficiency, not higher drug content per dose.

ANSWER: B

Rationale:

The three deiodinase isoforms (D1, D2, D3) are selenoproteins — they contain selenocysteine, the 21st amino acid, at the catalytic active site. Selenocysteine differs from cysteine in having selenium (Se) instead of sulfur (S) at the reactive site of the residue; selenium's lower reduction potential compared to sulfur makes selenocysteine a substantially more reactive nucleophile than cysteine, which is essential for the efficient thioredoxin-driven deiodination chemistry. Selenocysteine is encoded by UGA codons (normally read as stop codons) that are recoded as selenocysteine-incorporating codons in the presence of a SECIS (selenocysteine insertion sequence) element in the 3' untranslated region of the deiodinase mRNA, together with the specialized elongation factor EFSec and the selenocysteine-specific tRNA (Sec-tRNA[Sec]). Severe selenium deficiency — as occurs in geographic regions with very low soil selenium, in patients on long-term total parenteral nutrition without selenium supplementation, and in some malabsorptive states — impairs the synthesis of all three deiodinase isoforms. The resulting reduction in D1 activity reduces circulating T3 generation from T4 and slows rT3 clearance; reduction in D2 impairs intracellular T3 generation in brain and pituitary; reduction in D3 reduces fetal protection in pregnancy. The biochemical pattern of severe selenium deficiency can mimic central hypothyroidism with low or low-normal T3, normal or elevated T4, and elevated rT3, despite TSH secretory capacity being intact.

• Option A: Option A is incorrect because deiodinases do not use phosphoserine at their active sites; phosphoserine is a post-translational modification found on regulatory proteins and enzymes but is not the catalytic residue in deiodinases, which require selenocysteine.
• Option C: Option C is incorrect because deiodinases do not contain a zinc-coordinated cysteine cluster; zinc finger domains are found in transcription factors and certain metalloproteins, not in deiodinase catalytic sites, and zinc deficiency does not produce the described T4-high/T3-low pattern through deiodinase impairment.
• Option D: Option D is incorrect because deiodinases are not heme-containing iron-centered enzymes; cytochrome P450 enzymes use heme iron for oxidative catalysis, while deiodinases use selenocysteine for reductive deiodination — completely different chemistry.
• Option E: Option E is incorrect because deiodinases do not contain FAD cofactors; FAD-containing enzymes include flavoproteins involved in electron transfer chains and oxidative metabolism, not deiodinases, which rely on the thioredoxin/thioredoxin reductase system as their electron donor rather than FAD.

ANSWER: D

Rationale:

Lithium — used as a mood stabilizer in bipolar disorder — exerts several inhibitory effects on thyroid hormone physiology. Its primary mechanism at the thyroid gland is inhibition of thyroglobulin (Tg) proteolysis within follicular cell lysosomes: normally, TSH stimulates endocytosis of colloid into the thyrocyte, followed by fusion with lysosomes whose proteases (including cathepsin B, D, and L) cleave T4 and T3 from the Tg backbone. Lithium inhibits this lysosomal proteolytic step, trapping iodinated Tg within the follicular cell and reducing secretion of free T4 and T3 into the bloodstream. Lithium also inhibits iodide transport, contributing to reduced hormone synthesis. The resulting fall in circulating T4 and T3 drives compensatory TSH elevation, which stimulates follicular cell proliferation. Because secretion remains blocked while proliferative drive is maintained, follicular hyperplasia and colloid accumulation produce goiter — clinically detectable thyroid enlargement — in approximately 20–42% of long-term lithium users. Clinical hypothyroidism with elevated TSH develops in approximately 20–30% of patients (with higher rates in women and those with pre-existing autoimmune thyroid disease). Lithium is also sometimes used intentionally as an adjunct in thyroid storm because its secretion-blocking effect can complement thionamide therapy.

• Option A: Option A is incorrect because lithium's primary thyroid mechanism is inhibition of thyroglobulin proteolysis (and iodide transport), not NIS inhibition; NIS is the target of perchlorate (competitive inhibition) and high-dose iodide (autoregulatory downregulation) — not lithium's primary mechanism.
• Option B: Option B is incorrect because lithium does not irreversibly alkylate TPO; lithium is an inorganic monovalent cation (Li+) that modulates enzyme function through ion competition and signal transduction effects, not through covalent alkylation chemistry; thionamides are the TPO inhibitors used clinically.
• Option C: Option C is incorrect because lithium-associated hypothyroidism is primarily a direct pharmacological effect on thyroid hormone secretion and iodide transport, not autoantibody-mediated destruction; while lithium may increase the risk of autoimmune thyroiditis in predisposed individuals, the predominant mechanism in most patients is direct secretion blockade rather than a hapten-triggered autoimmune response.
• Option E: Option E is incorrect because lithium does not activate D3 within thyroid follicular cells; D3 is primarily expressed in peripheral tissues (placenta, fetal brain), and lithium's effects on thyroid hormone metabolism do not involve deiodinase activation; the described osmotic colloid cyst mechanism is fabricated and does not reflect any known lithium thyroid biology.

ANSWER: C

Rationale:

In addition to the well-characterized genomic mechanism of T3 binding nuclear TRs, displacing corepressors, recruiting coactivators, and altering gene transcription, thyroid hormones engage several non-genomic signaling pathways that operate within seconds to minutes and do not require new protein synthesis. The best-characterized plasma membrane-level non-genomic pathway involves T4 (and to a lesser extent T3) binding to integrin alphavbeta3 (αvβ3) — an adhesion molecule expressed on the plasma membrane surface of many cell types including endothelial cells and tumor cells. T4 binding to the RGD-recognition domain of αvβ3 activates the MAPK/ERK (mitogen-activated protein kinase/extracellular signal-regulated kinase) cascade, stimulating cell proliferation and angiogenesis. This pathway is pharmacologically relevant because tumor cells frequently overexpress integrin αvβ3, potentially exploiting the growth-promoting non-genomic T4 signaling; this has motivated interest in TR antagonists and T4 analogs that block αvβ3-mediated signaling without affecting genomic thyroid hormone action. T3 also activates PI3K (phosphatidylinositol 3-kinase)/Akt signaling through a cytoplasmic pool of TRbeta1, and T3 directly modulates ion channel conductances including HCN (hyperpolarization-activated cyclic nucleotide-gated) channels that regulate cardiac pacemaker rate — explaining both rapid cardiovascular responses in thyroid storm and the quick symptom improvement some patients report when converted to combination T3/T4 therapy.

• Option A: Option A is incorrect because the sympathomimetic manifestations of thyrotoxicosis are due to increased cardiac sensitivity to catecholamines (partly through beta-receptor upregulation driven by genomic TR signaling) rather than direct T3 phosphorylation of the beta-2 adrenergic receptor; propranolol provides symptom relief through beta-receptor blockade, not through inhibiting a T3-receptor phosphorylation pathway.
• Option B: Option B is incorrect because T4 does not non-specifically insert into membranes to alter fluidity as its primary non-genomic mechanism; the integrin αvβ3-MAPK pathway is a specific receptor-mediated mechanism, and non-specific membrane effects are not the established basis for the rapid actions of thyroid hormones.
• Option D: Option D is incorrect because T3-specific plasma membrane GPCRs (TAAR1/2/3) are not established non-genomic thyroid hormone receptors; TAAR1 is the receptor for trace amines and may interact with thyronamine derivatives, but it is not an established mediator of T3-driven cardiac rate acceleration in the hyperthyroid state.
• Option E: Option E is incorrect because non-genomic thyroid hormone signaling does involve plasma membrane receptors — specifically integrin αvβ3 as described; a cytoplasmic TRalpha1 isoform does participate in PI3K signaling, but direct physical interaction with voltage-gated sodium channel alpha subunits is not an established non-genomic thyroid hormone mechanism.